At 14,570, the Sensex might be close to a new high, but not all stocks have contributed to the rally.
Reliance Pharmaceuticals, the proposed pharmaceutical manufacturing company promoted by Mukesh Ambani's Reliance Life Sciences, will soon rope in a consultant to give final shape to the project, slated to take off within two years.
Despite having been in India for about 15 years and owning channels like MTV ,VHI and Nickelodeon, Viacom (CY2006 revenues $11.5bn) hasn't had much success. It's now joining hands with the TV18 group, a strong player in the news genre.
For a company that started in 1983 with just five people and five products, it's no mean achievement that Sun Pharma today commands the largest market capitalisation of Rs 21,271 crore (Rs 212.71 billion) in the pharma universe.
Elder Healthcare, an associated company of Elder Pharmaceuticals, will soon sign an inlicensing agreement with the Thailand-based herbal drug and personal care products manufacturer FCP Company to launch its products in India.
The World Health Organisation and the International Pharmaceutical Federation have joined hands with the Indian Pharmaceutical Association -- the national body of pharmacists in the country -- to upgrade the quality of services of 5.5 lakh pharmacies
Pharmaceutical industry experts said the US move had come as a boon for the Indian drug exporters as the law could clear the alleged doubts on the quality and the genuineness of Indian pharmaceutical and raw material products.
Shareholders of the world's fourth largest two-wheeler manufacturer, Bajaj Auto, have long hoped that some of the cash on the company's balance sheet would be returned to them in some form.
The $66 million (Rs 272.8 crore) Leiner Health Products is likely to sue DRL for the early divorce (the agreement has lasted only four years) from the alliance.
The world's largest manufacturer of healthcare products, Johnson & Johnson, is making India a global hub of its research and development as it looks to ramp up its pharmaceutical business in the country.
The increasing number of generic players tapping the US market for known molecules has resulted in pricing pressures and lean margins.
How domestic financial players are re-inventing themselves to get a larger share of the pie.
D Aravindakshan was the managing director of Kerala State Drugs and Pharmaceuticals at Alleppey for many years before taking over as the head of Agastya Biopharma
In a landmark judgment likely to benefit Indian generic drug manufacturers in a big way, the US Supreme Court has ruled against patenting of products with slight modifications.
In comparison, Indian companies received only 23 out of 139 final approvals (16.54 per cent) in the corresponding period in 2006.
There's talk that the Reliance Anil Dhirubhai Ambani Group is eyeing a minority stake in the carrier. It's also possible that private equity players like Texas Pacific Group may want a slice of the low-cost carrier's equity.
The Bangalore-based Himalaya Herbal Healthcare has struck strategic alliances with leading retail chains in its main export markets such as the US, Singapore and Malaysia.
Rural retailers are finding that helping farmers earn more helps them create a customer base.
Over 30 domestic pharmaceutical companies, including Ranbaxy, Cipla, Nicholas Piramal, Zydus Cadila and Torrent, face a possible ban on the sale of the generic version of Merck's pain management drug in the Indian market.
A recent court ruling in the US on allowing the declaratory judgment provision in the US patent law has come as a boost to Indian pharmaceutical companies such as Ranbaxy, Dr Reddy's, Sun Pharma and Lupin.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances